ADMA Biologics' GAAP loss for 3 months of 2022 was $25.008 million, up 36.1% from $18.38 million in the prior year. Revenue increased 81.3% to $29.103 million from $16.049 million a year earlier.
ADMA Biologics' GAAP loss for 3 months of 2022 was $25.008 million, up 36.1% from $18.38 million in the prior year. Revenue increased 81.3% to $29.103 million from $16.049 million a year earlier. 
admabiologics.com
English (US) 